ABSTRACT

Aim: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources.

Methods: From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They were divided into lung cancer group and breast cancer group. The clinical data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging was performed before and after bevacizumab treatment. The volume of tumor and brain edema were measured respectively.

Results: After treatment with bevacizumab, 72 cases of refractory brain edema were significantly relieved. The edema control rate was 93.75% in the lung cancer group and 77.14% in the breast cancer group (P < .05). The brain edema volume was significantly reduced after bevacizumab treatment from 198,286.84 ± 60,564.40 to 114,677.71 ± 42,337.38mm³ (P < .01), and the edema index was reduced from 26.14 ± 7.24 to 17.18 ± 5.14 (P < .01). Hypertension was observed in 14 cases.

Conclusion: Bevacizumab could significantly reduce refractory brain edema with a control rate of 86.75%. The efficacy of bevacizumab in the treatment of refractory brain edema caused by lung cancer is better than that of breast cancer.

摘要

目的：这项回顾性研究调查了贝伐单抗治疗不同来源脑转移瘤患者难治性脑水肿的效果。

方法： 2013年1月至2019年12月，对83例脑转移、难治性脑水肿患者进行贝伐单抗治疗。分为肺癌组和乳腺癌组。记录贝伐单抗的临床数据、疗效和副作用。在贝伐单抗治疗前后进行磁共振成像。分别测量肿瘤体积和脑水肿体积。

结果：经贝伐单抗治疗，72例难治性脑水肿明显缓解。肺癌组水肿控制率为93.75%，乳腺癌组为77.14%（P < .05）。贝伐单抗治疗后脑水肿体积由198,286.84 ± 60,564.40 显着降低至114,677.71 ± 42,337.38mm ³ (P < .01)，水肿指数从26.14 ± 7.24 降低至17.18 ± 5.14 (P < .01)。14例出现高血压。

结论：贝伐单抗可显着减轻难治性脑水肿，控制率为86.75%。贝伐单抗治疗肺癌所致难治性脑水肿的疗效优于乳腺癌。